BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 38673891)

  • 21. Ovarian cancer in endometriosis: clinical and molecular aspects.
    Lyttle B; Bernardi L; Pavone ME
    Minerva Ginecol; 2014 Apr; 66(2):155-64. PubMed ID: 24848074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Implications for Patients with Endometriosis.
    Wilbur MA; Shih IM; Segars JH; Fader AN
    Semin Reprod Med; 2017 Jan; 35(1):110-116. PubMed ID: 28049216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer.
    Banz C; Ungethuem U; Kuban RJ; Diedrich K; Lengyel E; Hornung D
    Fertil Steril; 2010 Sep; 94(4):1212-1217. PubMed ID: 19643405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis.
    Driva TS; Schatz C; Haybaeck J
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis.
    Fuseya C; Horiuchi A; Hayashi A; Suzuki A; Miyamoto T; Hayashi T; Shiozawa T
    Hum Pathol; 2012 Nov; 43(11):1964-72. PubMed ID: 22626277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer.
    Andersen CL; Boisen MM; Sikora MJ; Ma T; Tseng G; Suryawanshi S; Vlad A; Elishaev E; Edwards RP; Oesterreich S
    Horm Cancer; 2018 Dec; 9(6):399-407. PubMed ID: 30302736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovering the Deregulated Molecular Functions Involved in Malignant Transformation of Endometriosis to Endometriosis-Associated Ovarian Carcinoma Using a Data-Driven, Function-Based Analysis.
    Chang CM; Yang YP; Chuang JH; Chuang CM; Lin TW; Wang PH; Yu MH; Chang CC
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29113136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study.
    Erzen M; Rakar S; Klancnik B; Syrjänen K
    Gynecol Oncol; 2001 Oct; 83(1):100-8. PubMed ID: 11585420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometriosis-associated ovarian cancer: What have we learned so far?
    Herreros-Villanueva M; Chen CC; Tsai EM; Er TK
    Clin Chim Acta; 2019 Jun; 493():63-72. PubMed ID: 30776361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in LINE-1 methylation between endometriotic ovarian cyst and endometriosis-associated ovarian cancer.
    Senthong A; Kitkumthorn N; Rattanatanyong P; Khemapech N; Triratanachart S; Mutirangura A
    Int J Gynecol Cancer; 2014 Jan; 24(1):36-42. PubMed ID: 24304685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histologic Subtypes in Endometriosis-Associated Ovarian Cancer and Ovarian Cancer Arising in Endometriosis: A Systematic Review and Meta-Analysis.
    Chiaffarino F; Cipriani S; Ricci E; Esposito G; Parazzini F; Vercellini P
    Reprod Sci; 2024 Jun; 31(6):1642-1650. PubMed ID: 38438776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endometriosis-associated Ovarian Cancers.
    Anglesio MS; Yong PJ
    Clin Obstet Gynecol; 2017 Dec; 60(4):711-727. PubMed ID: 28990985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct molecular pathways in ovarian endometrioid adenocarcinoma with concurrent endometriosis.
    Zhang C; Wang X; Anaya Y; Parodi L; Cheng L; Anderson ML; Hawkins SM
    Int J Cancer; 2018 Nov; 143(10):2505-2515. PubMed ID: 30152524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study.
    Ishizaka A; Taguchi A; Tsuruga T; Maruyama M; Kawata A; Miyamoto Y; Tanikawa M; Ikemura M; Sone K; Mori M; Koga K; Ushiku T; Oda K; Osuga Y
    BMC Womens Health; 2022 Aug; 22(1):332. PubMed ID: 35932070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular, histologic, and molecular changes associated with endometriosis and ovarian cancer.
    Siufi Neto J; Kho RM; Siufi DF; Baracat EC; Anderson KS; Abrão MS
    J Minim Invasive Gynecol; 2014; 21(1):55-63. PubMed ID: 23962574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Risk factors of endometriosis associated ovarian carcinoma in women aged 45 years and older].
    He ZX; Wang S; Li ZF; Zhu L; Leng JH; Lang JH
    Zhonghua Fu Chan Ke Za Zhi; 2017 May; 52(5):314-319. PubMed ID: 28545269
    [No Abstract]   [Full Text] [Related]  

  • 37. Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype.
    Mandai M; Matsumura N; Baba T; Yamaguchi K; Hamanishi J; Konishi I
    Cancer Lett; 2011 Nov; 310(2):129-33. PubMed ID: 21802200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship of endometriosis and ovarian malignancy: a review.
    Nezhat F; Datta MS; Hanson V; Pejovic T; Nezhat C; Nezhat C
    Fertil Steril; 2008 Nov; 90(5):1559-70. PubMed ID: 18993168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endometriosis-associated ovarian cancer is a single entity with distinct clinicopathological characteristics.
    Li Q; Sun Y; Zhang X; Wang L; Wu W; Wu M; Meng C; Liu G
    Cancer Biol Ther; 2019; 20(7):1029-1034. PubMed ID: 30913953
    [No Abstract]   [Full Text] [Related]  

  • 40. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
    Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
    Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.